Clinical biomarkers of response in advanced renal cell carcinoma

Clinical biomarkers of response in advanced renal cell carcinoma

Item
http://www.wikidata.org/entity/Q26852564
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesIncidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trialsToxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsSunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma.Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium studyAssociation of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study.Sunitinib 2 weeks on, 1 off: strengths and weaknesses.Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction.
P2860

Clinical biomarkers of response in advanced renal cell carcinoma

Item
http://www.wikidata.org/entity/Q26852564
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical biomarkers of response in advanced renal cell carcinoma
@ast
Clinical biomarkers of response in advanced renal cell carcinoma
@en
Clinical biomarkers of response in advanced renal cell carcinoma
@nl
type
label
Clinical biomarkers of response in advanced renal cell carcinoma
@ast
Clinical biomarkers of response in advanced renal cell carcinoma
@en
Clinical biomarkers of response in advanced renal cell carcinoma
@nl
prefLabel
Clinical biomarkers of response in advanced renal cell carcinoma
@ast
Clinical biomarkers of response in advanced renal cell carcinoma
@en
Clinical biomarkers of response in advanced renal cell carcinoma
@nl
P1433
P1476
P2093
P304
P31
P3181
P356
P407
P433
P478
P577
P5875
P698
P921
P3181
P356
P1433
P1476
Clinical biomarkers of response in advanced renal cell carcinoma
@en
P2093
P304
P31
P3181
P356
P407
P433
P478
P577
P5875
P698
P921